Surface Oncology, Inc. (SURF)


+0.04 (+4.02%)
Symbol SURF
Price $0.957
Beta 1.615
Volume Avg. 0.32M
Market Cap 57.939M
Shares () -
52 Week Range 0.602-3.83
1y Target Est -
DCF Unlevered SURF DCF ->
DCF Levered SURF LDCF ->
ROE -52.58% Strong Sell
ROA -36.51% Strong Sell
Operating Margin -
Debt / Equity 60.98% Buy
P/E -
P/B 0.50 Buy


Consensus EPS

Upgrades & Downgrades

Latest SURF news

Mr. J. Jeffrey Goater
NASDAQ Global Market

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.